No Data
No Data
Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 28% Price Drop
Wells Fargo Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Maintains Target Price $2
Jefferies Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Cuts Target Price to $2
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
Unlock the Full List